Summary The effects of different doses of hydralazine and prostacyclin on the 31P magnetic resonance spectra of the LBDS, fibrosarcoma were investigated and related to their effects on mean arterial blood pressure (MABP) and heart rate. The effect of reducing MABP by bleeding the animals, via the tail artery, was also investigated. Tumour spectral changes following high dose drug treatment (an (Hahn, 1974; Overgaard & Bichel, 1977; Overgaard & Nielsen, 1980) . Hydralazine has also been shown to potentiate the cytotoxicity in solid rodent tumours in vivo of the bioreductive drugs RSU-1069 (Chaplin & Acker, 1987 and SR4233 (Brown, 1987) . These drugs are cytotoxic to hypoxic cells and their potentiation by hydralazine is presumably brought about by induced hypoxia secondary to a decrease in tumour blood flow.
Summary The effects of different doses of hydralazine and prostacyclin on the 31P magnetic resonance spectra of the LBDS, fibrosarcoma were investigated and related to their effects on mean arterial blood pressure (MABP) and heart rate. The effect of reducing MABP by bleeding the animals, via the tail artery, was also investigated. Tumour spectral changes following high dose drug treatment (an increase in inorganic phosphate, a reduction in nucleotide triphosphates and a reduction in pH) were consistent with nutrient deprivation. These changes were dose dependent. Changes in MABP and heart rate were consistent with vasodilatation in normal tissues. However, for the same fall in MABP, hydralazine produced a greater rise in tumour inorganic phosphate (Pi) and a greater fall in tumour pH than did prostacyclin. Controlled bleeding was effective in reducing MABP. It also reduced tumour pH but had no significant effect on tumour Pi. The clinical application of the two drugs for reducing tumour blood flow and pH for therapy is likely to be limited by the large degree of hypotension necessary to produce an effect. The differential effect of the two drugs for the same fall in MABP may be related to different degrees of direct tumour vasodilatation or to a direct effect of hydralazine on tumour energy metabolism. The observation that controlled bleeding does not change tumour Pi is further evidence indicating that the degree of arterial hypotension is not the sole factor in determining tumour energy status.
Drug-induced reduction in tumour blood flow is potentially advantageous for some forms of therapy. For instance, Horsman et al. (1989) have shown that the arteriolar vasodilator, hydralazine, can enhance hyperthermic damage in a C3H mammary carcinoma by decreasing the blood flow to the tumour. The enhancement was only partially due to more efficient tumour heating. The extra effect was most probably brought about by metabolic changes within the tumour and a decrease in extracellular pH. Although the thermosensitivity of cells is not changed by chronic adaptation to low pH, for instance (Hahn & Shiu, 1986) , acute metabolic changes and a decrease in pH are likely to occur following a decrease in tumour blood flow and these are known to sensitise cells to heat (Hahn, 1974; Overgaard & Bichel, 1977; Overgaard & Nielsen, 1980) . Hydralazine has also been shown to potentiate the cytotoxicity in solid rodent tumours in vivo of the bioreductive drugs RSU-1069 (Chaplin & Acker, 1987) and SR4233 (Brown, 1987) . These drugs are cytotoxic to hypoxic cells and their potentiation by hydralazine is presumably brought about by induced hypoxia secondary to a decrease in tumour blood flow.
Selective reduction of tumour blood flow also has potential in more conventional chemotherapy. Stratford et al. (1987) showed that a carefully timed administration of hydralazine could increase the cytotoxic action of melphalan in transplanted rodent tumours whilst normal tissue toxicity remained unaffected. This could be explained by a hydralazine-induced selective reduction in tumour blood flow leading to entrapment of melphalan in the tumour tissue.
Hydralazine is used clinically to control hypertension. Its plasma half-life in man is less than 60 min (Shepherd et al., 1980) , but its half-life in vascular smooth muscle may be as high as 30 h (Gross, 1977) which is a possible disadvantage for application in tumour therapy. Horsman et al. (1989) have shown that, in mice, the mean arterial blood pressure, which falls on administration of hydralazine, has not returned to normal 8 h after injection. Tumour blood flow was not measured directly but there was also some indication that it too had not returned to pre-drug levels by 8 h. Any longterm reduction in the tumour blood supply would be a disadvantage for radiotherapy. Therefore, in the present study, the effect of hydralazine on cardiovascular parameters and tumour energy metabolism was compared with that of prostacyclin, an endogenous vasodilator formed from arachidonic acid (Moncada et al., 1976 ). This compound is rapidly hydrolysed in whole blood and plasma with a half-life of around 6 min (Orchard & Robinson, 1981) . In man, the onset and offset of the cardiovascular actions of prostacyclin are rapid, less than 5 min, which means that its effects can be easily reversed (O'Grady et al., 1980; Lewis & Dollery, 1983) .
In order that the potential of hydralazine, prostacyclin and other vasoactive drugs (for review see Jain & Ward-Hartley, 1984) 
Materials and methods

Tumours
A transplanted rat fibrosarcoma, designated LBDS,, was used for these experiments. Details of the origin of this tumour and its maintenance have been described elsewhere (Tozer & Morris, 1990 Preliminary experiments were performed to determine the doses of hydralazine and prostacyclin which produced an iso-effect in terms of reduction in MABP. Two iso-effect doses were chosen. The 'high' iso-effect doses for the two drugs produced an initial reduction in MABP, during the first 20min following the start of drug administration, to approximately 55mmHg, and the 'low' doses an initial reduction to approximately 70mmHg. The high dose was 1 mg kg-' for hydralazine and 160 ng kg-' min-' for prostacyclin. The low dose was 0.1 mg kg-' for hydralazine and 10 ng kg-'min-' for prostacyclin. These doses were used to compare the effects of the two drugs on tumour 31P spectra for the same fall in MABP. A higher dose of prostacyclin (360 ng kg-l min-') was also used to determine the effects of hypotention below 50mmHg on tumour 31p spectra. Other doses were used to obtain dose-response curves for the two drugs.
The effects of 1 mg kg-' hydralazine and 160 ng kg-' min-' prostacyclin on MABP, systolic blood pressure, diastolic blood pressure, pulse pressure and heart rate were measured on separate groups of tumour-bearing catheterised animals using a physiological pressure transducer connected to a Gould RS3200 recorder.
31P magnetic resonance spectroscopy 31P MRS studies were carried out at 1.89T on an Oxford Research Systems TMR-32 spectrometer. Anaesthetised, catheterised rats were placed on two plastic tissue culture flasks containing recirculating warm water. The rats were positioned on their sides such that the flank tumour hung vertically downwards between the flasks and rested gently on a 20mm diameter, two-turn surface coil. This set-up was located within the horizontal bore of the magnet and minimised the risk of contamination of the tumour spectra by phosphates from underlying and adjacent normal tissue.
31P data were obtained in blocks of 10 or 20 min (from the sum of 300 or 600 free induction decays, respectively) with a pulse length of 10 gis and a pulse repetition time of 2 s. The resulting spectra therefore represented levels of phosphate metabolites averaged over the scanning period. The time for each scan was taken as the mid-point of each scanning period. The 900 pulse at the centre of this surface coil was 7 ,is. Data processing involved exponential weighting (equivalent to 15 Hz line broadening) and spectral deconvolution (to remove broad spectral lines) as described previously (Tozer et al., 1989) . Peak integration was performed by a computer programme which allowed operator definition of the baseline and peak limits.
Tumour pH (pHMRS) was evaluated from the chemical shift of the inorganic phosphate peak from the phosphocreatine peak using the calibration of Pritchard et al. (1983) .
Results Figure 1 shows examples of tumour 31P spectra obtained before and 5-25 min after bolus administration and the start of constant infusion of hydralazine and prostacycin respectively. Qualitative changes in the spectra following treatment are the same for the two drugs. The most significant changes are an increase in the inorganic phosphate (Pi) peak and a decrease in the nucleotide triphosphate (NTP) peaks. The phosphocreatine peak also tends to decrease. These changes are consistent with drug-induced nutrient deprivation of the tumours.
Since drugs were administered without disturbance of the animals' position within the magnet, it was possible to investigate changes of individual peak areas after drug administration. Peak areas were compared with their pre-drug levels using the Student's t test for paired data. Figure 2 shows changes in peak areas for inorganic phosphate (Pi), P-nucleotide triphosphate (P-NTP), phosphocreatine (PCr), phosphomonoesters (PME) and phosphodiesters (PDE) for a group of animals treated with hydralazine 1 mg kg-' (Figure 2a) and a group treated with prostacyclin 160ngkg-'min-' (Figure 2b ).
The peak area for Pi was doubled following injection of hydralazine. It remained elevated for the duration of the experiment (P<0.05), but with a gradual decline after the first 30 min post-drug towards control values. The P-NTP peak area decreased significantly after injection of hydralazine (P<0.05). There was some subsequent recovery but, at the end of the experiment P-NTP was still significantly below the pre-drug level (P = 0.04). PCr was significantly reduced in the first scan following injection (P = 0.02), but was not significantly reduced thereafter. Apparent changes in PME and PDE did not reach statistical significance with the animal numbers used.
The peak area for Pi was also significantly increased during the start of infusion of prostacyclin (P <0.05 for the first two scans after the start of infusion) ( Figure 2b ). However, this increase was not as large as for hydralazine and decreased back towards control values during the 60 min infusion. Changes in the other phosphates were more variable than for the hydralazine-treated animals. P-NTP was significantly reduced at the start of infusion (P = 0.01) but had returned to control values by the end. There were no very convincing changes in PCr, PME or PDE. Only the decrease in PDE during the first scan following start of infusion was statistically significant (P = 0.03). After stopping the infusion there was some indication of an increase in NTP and PCr above control levels, but these did not reach A -PCr, -U-PME, --0 --PDE.
statistical significance (P = 0.06 and 0.07 respectively) and had returned to control levels during the second 20 min scan post-infusion.
From Figure 2 Figure 3 shows the dose response of changes in Pi peak area following administration of hydralazine ( Figure 3a) and prostacyclin ( Figure 3b ). The lowest dose of hydralazine (0.1 mg kg-') and prostacyclin (10 ng kg-' min-) had no significant effect on tumour spectra. Higher doses of each drug produced a dose-dependent increase in Pi up to the highest doses used. The pattern of change in Pi was similar, for all effective doses, to those observed for the doses studied in Figure 2 . Hydralazine tended to cause an increase in Pi with a gradual reduction towards control levels at later times. Pi had returned to control levels by 220 min post-injection for 0.4 mg kg-' hydralazine (P = 0.53, Student's t test for paired data). This was not the case for 1.0 mg kg-' hydralazine where all values of Pi were above control levels (P<0.01). Prostacyclin caused an initial increase in Pi but with a rapid return towards control levels throughout the 60 min infusion. Pi returned to control levels after stopping the infusion. Figure 4a shows the effects of 1 mg kg-' hydralazine and Figure 4b of 160 ng kg-min'l prostacyclin on MABP and heart rate. Both drugs caused a significant decrease in MABP and increase in heart rate. Changes in MABP were dosedependent (results not shown). The initial fall in MABP was rapid for both drugs but there was some recovery over the 60 min infusion period for prostacyclin. This may be due to Figure  4a , is a well known sympathetic reflex response to the hypotension induced by this drug (Gross, 1977) . Prostacyclin, depending on the doses used and the basal heart rate, has been shown to induce both tachycardia, as a result of stimulation of baroreceptor reflexes, and bradycardia, due to stimulation of a vagal reflex (Chiavarelli et al., 1982) . In the present experiments, 160 ng kg-' min' prostacyclin was found to induce tachycardia (Figure 4b) output of dogs during infusion of prostacyclin (Armstrong et al., 1977) . Figure 5 shows the results for animals in which MABP was measured and tumour 31P spectra were collected simultaneously. One value for MABP was calculated over each 20 min scan period by averaging the MABPs read from the chart recording every minute. These values are plotted together with % change in Pi in Figure 5 for each spectrum collected over a total time of approximately 2 h. Time zero represents the time of bolus injection of hydralazine and start of infusion of prostacyclin. Prostacyclin infusion was stopped at 60 min. Figure 5a is for the high iso-effect doses of hydralazine and prostacyclin (1 mg kg-' and 160 ng kg-' min-' respectively). The mean reduction in MABP, between 0 and 60 min was very similar for the two drugs in this group of animals (dashed lines in Figue Sa). However, hydralazine is much more effective than prostacyclin in increasing Pi at these doses (continuous lines in Figure Sa) . The difference in Pi during the first scan post-drug for the two drugs does not quite reach statistical significance at the 5% level (P = 0.06, Student's t test for unpaired data). The difference in MABP is also not significant (P = 0.90). However, %Pi for hydralazine is significantly higher than for prostacyclin for the second and third scans post-drug (P = 0.002 and 0.001 respectively) despite no significant difference in MABP for the two treatment groups at these times (P = 0.06 and 0.11 respectively). During the fourth and fifth scans post-drug, %Pi is still significantly higher for hydralazine than for prostacyclin (P<0.001 for both scans), but the difference in MABP for the two treatment groups also becomes significant at these times (P = 0.01 for both scans). Figure Sb shows results for the low iso-effect doses of hydralazine and prostacyclin (0.1 mg kg-' and 10 ng kg-' Figure 5 The effect of high dose hydralazine (1 mg kg-') and prostacyclin (160ngkg-'min-') (a) and low dose hydralazine (0.1 mg kg-') and prostacyclin ( Figure 7 ) (P> 0.05 for each value of Pi compared to its pretreatment level, using the Student's t test for paired data). Tumour pH (pHMRS) was calculated for most of the spectra collected. However, sometimes this was not possible due to poor resolution of the PCr or Pi peaks. Figure 8a shows the change in tumour pH for high dose administration of hydralazine (1 mg kg-') and prostacyclin (160 ng kg-' min-'). The reduction in pH induced by hydralazine was significant (P<0.05 for each value of pH compared with its pretreatment level, using the Students' t test for paired data) up to 72 min post-injection. The reduction induced by prostacyclin was less than that induced by hydralazine but was still significant throughout the 60 min infusion (P <0.05). It had returned to pre-treatment values after stopping the infusion. Figure 8b shows the change in tumour pH for low dose administration of hydralazine (0.1 mg kg-') and prostacyclin (10 ng kg-' min'1). Tumour pH was significantly reduced from pre-drug levels at 30 min post-injection of hydralazine (P = 0.015, Student's t test for paired data) but there were no consistent changes with time and pH at the other time points > ' . ' ' ; r ; . , . ' i ' e ; ' ' * i . } . --t c -. e _ e ! [ -. Time (mnutes)F igure 8 The effect of hydralazine and prostacyclin administration and controlled bleeding on LBDS, tumour pH. a is for high drug doses (1 mg kg-' hydralazine, 160 ng kg-min-' prostacyclin). b is for low drug doses (0.1 mg kg-' hydralazine and 1O ng kg-min-' prostacyclin). c is for controlled bleeding. Times are the mid-points of spectral collections except that time 0 is the end of the first collection. Filled arrows in a and b represent the time of injection of hydralazine and the start of prostacyclin infusion. The arrow in c represents the start of withdrawal of blood. Values are means ± I s.e.m., n is the number of animals.
was not significantly different from pre-drug pH. Low dose prostacyclin had no significant effect on tumour pH during infusion. The reason for the fall in pH in this group of animals, after stopping the infusion, is not known.
The effect of controlled bleeding on tumour pH is shown in Figure 8c . Tumour pH was reduced significantly for the later time points (>40min) at which MABP was severely reduced (see Figure 7) . The reduction was very similar to that induced by 1 mg kg-' hydralazine for which there was also a comparable reduction in MABP.
The relationship between MABP and tumour Pi and-pH is complicated. Summarising the results:
1. High dose hydralazine (1 mg kg-') and high dose prostacyclin (160 ng kg-' min-' and 320 ng kg-' min-') caused substantial falls in MABP. Although the kinetics were different, both drugs were effective in increasing tumour Pi levels and reducing tumour pH.
2. Low dose hydralazine (0.1 mg kg-') and low dose prostacyclin (10 ng kg-min-') had no significant effect on tumour Pi levels and tumour pH despite a significant reduction in MABP for both drugs.
3. Hydralazine was more effective than prostacyclin in increasing tumour Pi levels and reducing tumour pH for the same initial fall in MABP.
4. Reduction in MABP by controlled bleeding was as effective as hydralazine (1 mg kg-1) in reducing tumour pH.
However, there was no increase in tumour Pi when MABP was reduced by this method.
Discussion
We have previously shown (Tozer et al., 1989 ) that the energy metabolism of transplanted rodent tumours is affected by their growth and by treatment with X-rays. These changes are most likely brought about by alterations in tumour blood flow.
Recent studies have shown that i.p. or i.v. administration of hydralazine to mice can decrease PCr, NTP and pH, and increase Pi in several murine tumours growing in different sites (Okunieff et al., 1988; Dunn et al., 1989) . Our results are broadly in agreement with these findings. The spectral changes brought about by high dose treatment with hydralazine or prostacyclin are most likely to be largely due to changes in tumour blood flow. A reduction in tumour blood flow has been demonstrated in dogs and in rodents following administration of hydralazine Horsman et al., 1989) . A hydralazine-induced increase in blood flow to normal tissues, without a reduction in tumour blood flow itself, has also been demonstrated, causing a reduction in the ratio of tumour to normal tissue blood flow Chan et al., 1984) . The effect of prostacyclin on tumour blood flow has not been studied.
In the present study, tachycardia, following administration of hydralazine and prostacyclin, suggests an increase in cardiac output in an attempt to compensate for the hypotension (cardiac output =heart rate x stroke volume). Vasoactive agents can modify tumour blood flow directly via changes in tumour vascular resistance or indirectly via changes in blood pressure (blood flow through a tissue = arteriovenous pressure difference -. vascular resistance). The direct effect is likely to be less than that in normal tissues because tumour blood vessels are generally less well endowed with vascular smooth muscle than normal tissue blood vessels (Warren, 1979) . Therefore, any potential drug-induced increase in tumour blood flow resulting from vasodilation of tumour blood vessels and a decrease in vascular resistance was probably masked, in the present experiments, by the hypotensive effect of the two drugs at all doses used. Where there are minimal effects on MABP it is possible to demonstrate an increase in PCr/Pi of animal tumours (Okunieff et al., 1988) . At very high doses of the drugs, it is possible that the reduction in tumour blood flow brought about by hypotension is compounded by vascular collapse resulting from a reduction in intravascular pressure to below that of the interstitial pressure (Jain, 1988) . This is more likely to occur in tumours than in normal tissues because of their high interstitial pressure (Wiig et al., 1982) . Horsman et al. (1989) showed that the radiobiologically hypoxic fraction of a C3H mouse mammary tumour increased and its blood flow decreased following administration of hydralazine. Hypoxia, in the rat fibrosarcoma, resulting from a decrease in tumour blood flow would be expected to cause the observed increase in Pi, decrease in NTP and decrease in PCr of this tumour via the enzyme reactions catalysed by adenylate kinase and creatine kinase. Tumour pH would also be expected to decrease, in the initial stages before depletion of glucose, as a result of an increase in anaerobic glycolysis.
A large reduction in MABP was necessary, for both hydralazine and prostacyclin administration, before any effects on tumour spectra were observed. 'Low dose' hydralazine and prostacyclin caused MABP to fall to approximately (Lewis & Dollery, 1983) . The whole question of artefacts introduced into spectral measurements by the use of general anaesthesia is an important one. Unfortunately, we have not found a satisfactory method for sufficiently restraining conscious rats for 31P MRS without causing the animals considerable stress. However, the fact that the results of Okunieff et al. (1988) , for hydralazine administration to conscious mice, are similar to ours, suggests that anaesthesia is not qualitatively affecting the results.
Despite the reservations regarding effective doses, it is still possible that drugs such as hydralazine and prostacyclin may be clinically useful. Firstly, the sensitivity of changes in energy metabolism, as a marker for changes in tumour blood flow, is not known. Therefore, it is possible that a moderate reduction in tumour blood flow may occur for a moderate fall in MABP. This is suggested by the work of Vaupel (1975) . Secondly, an increase in blood flow to the normal tissue surrounding the tumour may occur at moderate reductions in MABP for which tumour blood flow is unchanged. Either of these possibilities would facilitate, for instance, tumour heating for hyperthermia treatments. This would be beneficial, even in the absence of increased thermal sensitivity gained from nutrient deprivation of the tumour itself.
The potential advantage of the short biological half-life of prostacyclin compared with that of hydralazine was outweighed by its apparent reduced effect on spectral parameters for the same initial reduction in MABP. The reason for this differential effect is unclear. Hydralazine acts directly on the vascular smooth muscle of arterioles for its vasodilatory effect although its exact mechanism of action is unknown. Vasodilatation by prostacyclin results from its stimulation of adenylate cyclase which raises intracellular levels of cyclic adenosine monophosphate (Weksler, 1984; Hopkins & Gorman, 1981) . This general effect is likely to result in dilatation of al! :ypes of blood vessels endowed with smooth muscle.
The net affect of vasodilator on tumour blood flow will be dependent on a balance between its indirect effects arising from hypotension caused by vasodilatation in normal tissues and direct effects arising from dilatation of the tumour blood vessels themselves. It is therefore possible that prostacyclin has a greater direct dilatory effect on tumour blood vessels than hydralazine. This would tend to counteract the indirect effect of a fall in MABP and maintain blood flow through the tumour. The possibility of direct dilatation of tumour blood vessels depends on (1) their smooth muscle investment, (2) their vascular tone and (3) possession of the relevant receptors. Tumour blood vessels are generally rather poorly endowed with vascular smooth muscle (for review of tumour vascular morphology see Warren (1979) ). However, normal blood vessels may be incorporated into the tumour mass during its growth and this will depend upon tumour type (Falk, 1977) . Smooth muscle investment also depends upon the size of blood vessels. Falk (1977) found that, for one particular type of fibrosarcoma, both veins and arteries retained a muscular investment until the branching became very fine. Receptor analyses of tumour blood vessels have not been carried out. The balance between indirect and direct effects of vasoactive agents on tumour blood flow has been discussed by Jirtle (1988) . The possibility of direct dilatation or constriction of tumour blood vessels requires specific investigation before the therapeutic potential of vasoactive agents can be properly exploited.
Other characteristics of the two drugs could produce a differential effect on tumour blood flow. Prostacyclin is antiaggregatory for platelets (Pace-Asciak & Gryglewski, 1983 ).
This may be important if platelet aggregation in tumours is significant. Vasodilatation in the normal tissues surrounding the tuniour may also be different for the two drugs for the same level of hypotension. We are currently investigating whether the differential effect of hydralazine and prostacyclin in tumour energy metabolism is reflected by a similar differential effect on tumour blood flow.
A direct biochemical effect of hydralazine could also play a role in its effect on tumour energy metabolism. It is known that hydralazine inhibits the action of various enzymes and this may be associated with its ability to chelate metal ions such as Fe2 , Fe3`and Cu2+ (Gross, 1977) . Hydralazine is metabolised in the body by acetylation via acetyl coenzyme a which is an ATP requiring process (Douglass et al., 1957) . It is also known (Gross, 1977) that sublethal doses of hydralazine can reduce levels ofhigh energy phosphates in the brain and depress oxygen uptake in preparations of brain, liver and kidney of rats.
Depite the relationship demonstrated between drug-induced systemic hypotension and tumour Pi (Figure 6 ), systemic hypotension is not, on its own, a good indication of changes in the tumour micro-environment. This is illustrated by the spectral changes observed for rats whose MABP was reduced by controlled bleeding. Reduction of MABP to levels comparable with those induced by hydralazine was obtained by this method. However, although tumour pH was also reduced comparably, tumour Pi remained unchanged. This result is difficult to explain. Vaupel (1975) has investigated the effect of controlled bleeding on MABP and blood flow in the DS-carcino-sarcoma implanted into rat kidneys. He showed that blood flow was linearly related to MABP within the range of 40-135 mmHg. If this is the case for the subcutaneous fibrosarcoma in the current experiments then one would expect Pi to be significantly affected. Catecholamine release, due to blood loss, would tend to increase glycolysis and this may be sufficient to maintain high energy phosphate levels under these conditions. An increase in lactate levels would then explain the decrease in pH. Another possiblity is that venous pressure will be reduced following controlled bleeding and this may, in turn, reduce tumour interstitial pressure. Such a reduction could maintain tumour blood flow despite a fall in arterial blood pressure. Obviously the relationship between MABP, tumour phosphate levels and tumour pH is very complicated and requires further investigation.
In conclusion, 31P MRS was useful for monitoring the effects of vasoactive drugs on tumour energy metabolism. Vasoactive drugs such as hydralazine and prostacyclin, which appear to affect tumour energy metabolism primarily via their vasodilatory effects on normal tissues, which reduces systemic blood pressure, may be ineffective in altering tumour energy metabolism clinically because of the severe systemic hypotension involved. The differential between the effects of hydralazine, prostacyclin and controlled bleeding on tumour energy metabolism, for the same degree of systemic hypotension, suggests further studies on the direct versus indirect effects ofhydralazine on tumour energy metabolism. This would be desirable for a systematic approach to finding methods for manipulating tumour blood flow for optimisation of therapy.
